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Abstract 
Bone health status is largely absent in South Africa, the main reasons being the absence and cost-effectiveness of 
specific screening equipment for assessing bone mineral density (BMD). Various risk factors seem to play a role, some 
of which can be modified to change bone health status. Urbanisation is also a public health concern. Changing nutri-
tional, as well as social behaviour, play integral roles in the prevalence and incidence of decreased BMD. Furthermore, 
human immunodeficiency virus (HIV) specifically, has a negative impact on BMD and although highly active antiretro-
viral therapy increases the prognosis for HIV-infected individuals, BMD still seem to decrease further. Dual energy X-ray 
absorptiometry is considered the gold standard for BMD assessment; however, recent developments have provided 
more cost-effective screening methods, among which heel quantitative ultrasound appears to be the most widely 
used in resource limited countries such as South Africa.
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Background
Osteoporosis, the most common metabolic bone disease, 
affects almost a quarter of all postmenopausal Cauca-
sian women, the lifetime risk of fracture in these women 
being 30–40% compared to 20% in men (Fig.  1a) [1]. 
Worldwide, this risk can vary up to tenfold, depending 
on the country of origin—the greatest risk reported for 
the United States of America (USA) [2]. Global statistics 
regarding the prevalence of osteoporosis, bone mineral 
density (BMD) and fracture risk are readily available for 
international countries due to the continuous access to 
expensive equipment that can screen for bone mass.
The World Health Organization (WHO) developed the 
Fracture Risk Assessment Tool (FRAX) in order to deter-
mine a 10-year probability of the potential risk for future 
hip fractures or major osteoporotic fractures in women 
and men between the ages of 40 and 90 years, by using 
different risk factors related to BMD [3]. In 2000, the 
incidence of osteoporotic fractures was estimated to be 
nine million worldwide, with hip fractures contributing 
1.6 million (Fig.  1b) [4]. In 2010, projections for the 
USA (according to FRAX) indicated that approximately 
52.4 million individuals older than the age of 50  years 
would develop low bone mass and osteoporosis [5]. Fur-
thermore, it was predicted that approximately 14 mil-
lion individuals would be diagnosed with osteoporosis, 
whereas 47 million will be more likely to have low bone 
mass in 2020 (Fig.  1c). Since osteoporosis is the most 
common cause for fractures, it accounts for approxi-
mately 1.5 million fractures each year—hip fractures is 
projected to increase to 6.3 million by 2050, while osteo-
porosis is projected to increase exponentially due to the 
aging of the population (Fig.  1b) [6]. Fragility fractures, 
fractures that occur as a result of a fall from a standing 
height, lower, or from no trauma at all, can also impact 
FRAX scoring, although this is poorly understood.
According to the clinical guideline published by the 
National Osteoporosis Foundation of South Africa 
(NOFSA) in 2010, the incidence of osteoporosis in white, 
Asian and mixed race populations in South Africa (SA) 
seems to be similar to that observed in developed coun-
tries, although no accurate fracture data exists for SA [1]. 
Osteoporosis appears to be less prevalent in SA black 
populations, similar to data for the USA, although some 
studies show contradictory results [7–9]. The reasoning 
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behind this being the contribution of fat mass, more spe-
cifically visceral adipose tissue (VAT), compared to skel-
etal muscle mass. What is somewhat concerning is that 
according to a recent extended report by Sanchez-Riera 
et  al. on the global burden attributable to low BMD as 
measured by dual energy X-ray absorptiometry (DEXA), 
no data on BMD at the femoral neck is available for sub 
Saharan Africa (East and Central), whereas only two 
studies have reported on BMD in West sub Saharan 
Africa, and one in South sub Saharan Africa [10].
Bone mineral density (BMD)
Definition, classification and guidelines
Bone mineral density (or bone density), a quantita-
tive measurement of bone mass referring to the amount 
of mineral matter (calcium) in grams per square centime-
tre  (cm2) of bones [11, 12], is used in clinical medicine 
as a surrogate indicator of osteoporosis and fracture risk. 
According to the National Institutes of Health Consensus 
Development Panel on Osteoporosis Prevention, Diagno-
sis, and Therapy, osteoporosis can be defined as a skeletal 
disorder characterized by increased fracture risk and low 
bone strength [13].
Several guidelines for the diagnosis and management of 
osteoporosis have been proposed in 1994 by the WHO. 
Hough et al. summarized these guidelines into one docu-
ment for NOFSA [14]. According to the WHO, a subject’s 
BMD is expressed in relation to a young adult refer-
ence mean for female Caucasians (T-score) and grouped 
accordingly into either normal, low bone mass or osteo-
penia, osteoporotic, and severe osteoporotic categories 
[14].
The WHO’s diagnostic criteria for osteoporosis is a 
BMD measurement equal to or more than 2.5 stand-
ard deviations (SD) below the young female (aged 
20–29  years) reference mean (T-score  ≤−2.5 SD), 
whereas a patient is diagnosed with osteopenia if they 
have a T-score between −1.0 and −2.5, and as normal if 
they have a T-score between 1.0 and −0.9 [14].
According to the WHO, T-scores should be reserved 
for diagnostic use in postmenopausal women and men 
aged 50 years or more only [14]. For all other populations, 
Z-scores should be used instead, although categorising 
individuals as either osteopenia or osteoporotic should 
still be acceptable for the femoral neck. The Z-score, 
calculated in the same manner as the T-score, com-
pares a person’s bone density to that of an age-, sex-, and 
race-matched population. This scoring system is usu-
ally reserved for youngsters and adolescents; however, 
considering that these individuals are still growing, the 
Z-score should also account for pubertal stage and body 
size. Specialists should also be cautious when diagnosing 
osteoporosis (a Z-score of ≤−2.0) in children with this 
scoring system, as one also needs to consider the pres-
ence of at least one fragility fracture [15]. Seeing that the 
Z-score is age-matched, it can also point to a secondary 
cause of osteoporosis, other than age in older individuals 
[16].
Physiology and pathophysiology
In order to fully comprehend the debilitating effects of 
osteoporosis, a short summary of the natural life history 
of BMD acquisition and loss is included. Normally, dur-
ing childhood and the teenage years, bone density accu-
mulates and bone grows in both size and strength (growth 
phase), as new bone is added to the skeleton faster than 
old bone is removed or resorbed (Fig. 2) [17]. After the 
growth spurt stops, bone formation continues faster than 
resorption until peak bone mass is reached at about age 
25–30 [18, 19]. Bone density is then maintained for about 
10 years, at which point bone mass may remain relatively 
stable (remodelling phase), whereafter the age of 35, both 
men and women will gradually lose 0.3–0.5% of their 
bone density per year as part of the aging process [20, 
Fig. 1 Representative data indicating (a) the lifetime risk of fractures, (b) the incidence of fractures and (c) the incidence of low bone mass and 
osteoporosis
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21]. Between the ages of 45 and 55, the menstrual cycle 
in women ceases, at which point women start to loose 
bone rapidly in the first 4–8 years thereafter, as a result of 
decreased oestrogen production [22]. By age 65, men and 
women tend to lose bone tissue at the same rate, which is 
much more gradual and continues throughout life.
Considering normal bone growth, osteoporosis is 
thought of as a silent disease, since bone loss usually 
occurs without any signs or symptoms. It is also charac-
terized by low BMD, increased bone turnover and dete-
rioration of bone microarchitecture [23]. Although BMD 
is used in the diagnosis of osteoporosis, low BMD is not 
the only risk factor for fractures and is not often used on 
its own to identify fracture risk [24].
Various risk factors are associated with the devel-
opment of osteoporosis. These include unmodifiable 
risk factors such as age (the older, the more at risk), sex 
(females are more at risk), ethnicity (variable results, 
but pointing towards non-caucasians being more at 
risk), family history of osteoporosis (immediate family) 
and prior vertebral fracture or fragility fracture [24–26]. 
Modifiable risk factors include low body mass index 
(BMI), particularly in postmenopausal women, exposure 
to oestrogen, physical activity, long-term glucocorticoid 
treatment and long-term anticonvulsant therapy (phe-
nytoin, phenobarbital and carbamazephine) [24–26]. 
Additionally, nutritional status also plays a significant 
role—impaired absorption or low dietary intake of vita-
min D and calcium and excessive use of alcohol (>3 units 
per day) and tobacco are also risk factors for low BMD 
[27]. Secondary causes for osteoporosis also exist and 
include type 1 diabetes, rheumatoid arthritis osteogen-
esis imperfect (brittle bone disease) in adults, anorexia 
nervosa, hyperparathyroidism, untreated long-standing 
hyperthyroidism, hypogonadism or premature meno-
pause (<45 years), chronic malnutrition or malabsorption 
(e.g. coeliac disease, inflammatory bowel disease) and 
chronic liver disease.
Currently, the WHO uses the FRAX index assessment 
tool to predict fracture risk for a 10 year period in peo-
ple with low BMD by incorporating various clinical risk 
factors in its calculation [28]. These include age, sex, 
race, height, weight, body mass index, fracture history 
of the patient and parent, current smoking, glucocorti-
coid usage, the presence of rheumatoid arthritis, second-
ary causes of osteoporosis, alcohol intake and the BMD 
measure of the femoral neck. It has been suggested that 
FRAX only be used to calculate fracture risk for patients 
who have T-scores between −1.0 and −2.5 in the spine, 
femoral neck, or total hip region, but not when patients 
are already on pharmacologic treatment for osteoporo-
sis. According to NOFSA, treatment should also only be 
considered when the 10-year risk of major-osteoporo-
tic-related fractures as calculated by FRAX are  ≥20% 
[29, 30]. Although FRAX includes a vast number of 
risk factors, it neglects other important factors, such as 
25-hydroxyvitamin D [25(OH)D], physical activity, risk of 
falls, and biochemical bone markers. Furthermore, mul-
tiple risk factors could account for the presence of sec-
ondary osteoporosis; however, the risk score does not 
distinguish between any of these risk factors, which could 
impact the predicted risk differently.
Different methods exist to assess BMD. These methods 
will be discussed in the next section, with specific focus 
on the advantages and disadvantages of each.
Bone mineral density assessment methods
Dual energy X‑ray absorptiometry (DEXA)
The use of DEXA in the diagnosis and management of 
osteoporosis is considered the gold standard to deter-
mine loss of BMD [31]. Despite being considered the 
best clinical tool for diagnosing osteoporosis, DEXA does 
have some limitations. The biggest critique is that it is 
influenced by bone size, which suggests that the larger 
the bone, the greater the BMD, irrespective of its volume. 
This poses a potential problem since men display higher 
BMD, even though they might have similar or lower vol-
umetric bone mineral density (vBMD) [32]. Furthermore, 
two-dimensional (2D) DEXA can also be influenced by 
artefacts such as aortic calcification and degenerative 
changes in the spine [23]. Nonetheless, and even though a 
skilled operator is necessary for its interpretation, DEXA 
is known for its speed, low radiation dose, moderate cost 
and ease of operation [33]. In the SA setting specifically, 
DEXA is not readily available in all clinics; therefore, var-
ious other diagnostic assessment tools are implemented 
Fig. 2 The general pattern of bone development and loss over 
time. During years 0–20, bone starts to grow, during the ages of 
20–30 years, modelling takes place and peak bone growth is reached. 
This is followed by the remodelling phase where bone loss is evident
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to determine BMD. Although BMD can be assessed with 
other imaging tools, the DEXA T-score must be used as 
reference standard to compare and validate other BMD 
modalities.
Quantitative computed tomography (QCT)
In contrast to DEXA which provides 2D scans of bone, 
quantitative computed tomography (QCT) provides 
three-dimensional (3D) measures of vBMD with the 
potential to examine specific compartments within the 
body separately, such as trabecular and cortical bone, 
as well as provides a better estimate of the bones’ cross-
sectional geometry (bone shape and size) [34, 35]. This 
technique is usually used in conjunction with DEXA for 
better prediction of fracture risk and osteoporosis, as 
QCT is predominantly perceived as a research tool [34].
Volumetric QCT is regarded as a quicker and techni-
cally less demanding acquisition tool, even though skill 
is required for its interpretation, and is more widely 
available since a whole body scanner can be used for 
image analysis with high precision. However, the indi-
vidual being scanned is exposed to modest radiation, 
and depending on the resolution, an increased radia-
tion dose is often required. Results from the study by 
Pickhardt et al. suggest that both QCT and simple non-
angled region-of-interest (ROI) attenuation measure-
ments (measures employed in colonography CT, CTC) 
of the lumbar spine are effective for BMD screening [36]. 
Data also suggests that single-level ROI vertebral attenu-
ation measurement at CTC is reproducible, requires lit-
tle effort, and adds no additional radiation or costs, but 
can provide valuable BMD data for osteoporosis screen-
ing [37]. Furthermore, by applying either QCT analysis to 
non-contrast-enhanced CT studies, individuals at risk for 
osteoporosis can be identified. However, a DEXA scan 
is still needed if an individual at risk for osteoporosis is 
identified, even though it has been suggested that QCT 
may be better for BMD assessment [38].
Magnetic resonance imaging (MRI)
Conventional proton magnetic resonance imaging (MRI) 
is one of the few non-radiative methods used to char-
acterize bone based on mineral and matrix, and pro-
duces a negative image of the bone substance [39]. The 
microarchitectural details of the trabecular network of 
the bone is geometrically analysed to determine the vol-
ume of the bone substance (similar to BMD) if an image 
is produced in which one can differentiate between the 
marrow spaces and the trabeculae of the bone, which is 
most often a difficult task in human subjects [39]. How-
ever, if the image has insufficient dimensional resolution, 
textural information can be obtained about the trabecu-
lar network of the bone which may be related to bone 
mass [40, 41]. It is this ability of MRI to reflect the micro 
physiology of tissues that makes it such a powerful tool 
allowing it to better differentiate patients with and with-
out osteoporotic fractures compared to normal BMD. 
More specifically, the ability to use MRI for vBMD cal-
culations without losing soft tissue signals makes it more 
clinically attractive even though using MRI to quantify 
BMD is somewhat difficult due to the low proton signals 
in mineral [42].
Several improvements have been made to MRI to 
overcome the problem of low proton signals. Solid state 
P31 nuclear magnetic resonance projection MRI have 
been developed which enhances the phosphorus sig-
nals to determine BMD more accurately [42], as well as 
the more recent development of ultra-short echo MRI 
[43]. Furthermore, high-resolution MRI has been devel-
oped in order to quantify the trabecular architecture at 
the micro-meter level [44, 45], a difficult process which 
requires standardization at each stage (high resolution 
MR images consists of several stages) in order to ensure 
a high degree of reproducibility [46]. Although various 
studies have been performed in order to optimize image 
acquisition, post processing, calibration and validation 
of measurements using MRI, these methods remain 
technically challenging if not performed by a trained 
professional.
Quantitative ultrasound (QUS)
Recent developments in densitometry technology have 
provided alternative methods, among which heel quan-
titative ultrasound (QUS) appears to be the most widely 
used. According to the ISCD, calcaneal QUS is the only 
recognized measurement of QUS to determine bone 
health status due to the abundance of research done 
on this particular bone compared to other bone seg-
ments [47]. QUS, albeit inexpensive, portable, ionizing-
radiation-free and proven to predict hip fractures and 
all osteoporotic fractures in Caucasian postmenopausal 
women and elderly men, also requires a trained techni-
cian to interpret the results obtained [48, 49]. QUS of 
the calcaneus has also been shown to accurately predict 
osteoporotic fractures in elderly female populations [49]. 
Furthermore, it has the potential to separate osteoporotic 
individuals from healthy bone individuals [28].
Some of the key features of QUS are its ability to meas-
ure the speed of a sound wave (SOS in meter per sec-
ond—m/s) and its attenuation as it travels through bone. 
The latter is termed broadband ultrasound attenuation 
(BUA, dB/mHz), which occurs as a result of the energy 
that is absorbed by the soft tissue and bone when the 
sound waves travel through them. It has also been shown 
that SOS correlates well with BMD [50, 51], whereas 
BUA is influenced by certain structural characteristics of 
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trabecular bone, such as porosity [50, 52]. A more com-
plex parameter has also been developed from the combi-
nation of SOS and BUA, and is used to measure stiffness. 
This is termed the stiffness index (SI) and has been shown 
to be more useful in identifying subjects with low BMD 
and thus high fracture risk [53]. Studies by Gonnelli et al. 
and Mészáros et  al. indicated that both SOS and BUA 
can be used to distinguish between individuals with and 
without fractures, however, SOS seem to be somewhat 
more useful in men [54, 55]. In contrast, according to a 
study by Ndongo et al., BUA was the most useful meas-
ure for identifying factors associated with bone status, 
such as age, weight and physical activity in urban Senga-
lese women [56].
Due to the fact that the principles behind QUS and 
DEXA’s ability to determine bone health differs, the same 
cut-off points may not be useful for both QUS and DEXA 
[47], as DEXA’s cut-offs may over/underestimate the true 
incidence of osteoporosis [57]. Although DEXA is the 
standard reference method for diagnosing osteoporosis, a 
recent study in Dakar, Senegal have employed ultrasound 
to determine BMD and have found it a useful tool for 
assessing BMD especially in areas where DEXA is una-
vailable as is often the case in SA [58]. In this particular 
study, human immunodeficiency virus (HIV)-infected 
patients have reduced QUS BMD in comparison with 
subjects from the general population. However, there 
was no association between QUS BMD and duration of 
treatment—at least 5 years on highly active antiretroviral 
therapy (HAART). Since the validated reference method 
for bone density assessment couldn’t be used, the clini-
cal significance of these results in terms of osteoporosis 
remains unknown.
It is evident from the studies mentioned above that 
QUS has the potential to not only predict fracture risk, 
but also to determine BMD. To complement the results 
obtained with QUS, specific biochemical markers can be 
used in conjunction with BMD testing to determine bone 
health status.
Biochemical‑specific markers
Bone turnover markers Bone turnover is the main con-
tributor to both quality and quantity of bone. An imbal-
ance between bone resorption and formation leads to a net 
loss or gain of bone tissue. High bone turnover results in 
bone loss and abnormal bone microarchitecture, whereas, 
low bone turnover results in increased bone mass, accu-
mulation of microdamage, and bone fragility [59].
Surrogate markers of fracture risk—bone turnover 
markers (BTMs) and BMD—can be used to monitor a 
specific treatment response. High levels of bone BTMs 
were shown to correlate well with increased fracture 
risk in postmenopausal women [60]. In various studies 
regarding therapeutic agents, BMD and BTMs were 
shown to respond differently, a change in BMD only 
observed after about 1–2 years [61], whereas changes in 
urinary levels of BTMs were observed within a couple of 
months [62, 63]. In a study by Bjarnason et al., short-term 
changes (3–6 months) in BTM was associated with long-
term changes (1–2  years) in BMD, therefore both BTM 
and BMD can be used, albeit at different times [64].
Although several studies have investigated numer-
ous biochemical markers of bone turnover to determine 
fracture risk, it was recommended by Vasikaran et  al. 
to use serum carboxy terminal telopeptide of collagen 
type I (s-CTX) as the standard bone resorption marker 
and serum procollagen type I N-terminal propeptide 
(s-PINP) as the standard bone formation marker [65]. 
Serum CTX is shown to be specifically influenced by 
renal function, diurnal rhythm and food intake, peaking 
early in the morning and is at its lowest in the afternoon. 
Food intake also tends to decrease these levels; therefore, 
it is imperative that sampling time be in the morning and 
in a fasted state. Serum PINP on the other hand is not 
influenced that greatly by diurnal rhythm, food intake or 
temperature.
Biochemical and nutritional markers Several biochemi-
cal markers can also be assessed to determine the contrib-
uting factors associated with osteoporosis. These include 
serum total calcium, albumin (to correct for calcium if data 
is skewed by abnormal albumin) and phosphate amongst 
others to detect conditions associated with hypercalce-
mia, such as primary hyperparathyroidism or hypocal-
cemia and consequent secondary hyperparathyroidism 
causing bone loss [66]. Serum creatinine measurements 
and estimations of the glomerular filtration rate are also 
useful to detect renal failure which can affect bone health 
[66]. Although serum alkaline phosphatase (ALP) is a use-
ful marker to detect certain disease conditions regarding 
bone, it is not sensitive enough to detect changes in bone 
remodelling [66].
Adequate supply of vitamin D is considered essential 
for bone health as it aids calcium absorption in order 
to maintain the calcium concentration in the physio-
logically-relevant range [67, 68]. Vitamin D levels are 
directly related to BMD irrespective of ethnicity and gen-
der, maximum density achieved with levels of 40 ng/mL 
(99.8 nmol/L) or higher [69]. Since vitamin D is vital to 
the regulation of calcium and phosphorous metabolism, 
bone formation and mineralization, it is documented 
as one of the key factors associated with bone mass and 
therefore important in the management of osteoporosis 
[70]. Although the optimum level of serum 25(OH)D (the 
inactive form of vitamin D) in a healthy population is not 
uniformly accepted, a concentration of at least 30 ng/mL 
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(75  nmol/L) is recognised as the endpoint (lowest) for 
skeletal health outcomes by most [70–72], whereas 20 
up to 30 ng/mL (50–75 nmol/L) is considered acceptable 
and desirable [73].
Exposure of the skin to sunlight, the melanin con-
centration, clothing style when exposed to sunlight and 
the season all play important roles in vitamin D pro-
duction [74, 75]. Age, BMI, vitamin D supplementation 
and physical activity also influence the concentration of 
serum 25(OH)D [72, 75]. Furthermore, serum 25(OH)D 
concentration also positively correlates with BMD and 
negatively with parathyroid hormone (PTH) [76–79], and 
it was determined that serum PTH tended to be higher 
in individuals with serum 25(OH)D between 50 and 
75 nmol/L (20 up to 30 ng/mL), a concentration sufficient 
to prevent secondary hyperparathyroidism. PTH is pri-
marily responsible for converting 25(OH)D in the kidney 
to the hormonal, active form of 1,25(OH)2D. However, 
many other tissues in the body are also able to instigate 
this conversion in order to act locally as a paracrine or 
autocrine hormone [80].
Directly linked to vitamin D’s role in calcium homeo-
stasis, is the relationship between calcium and PTH 
(Fig. 3). When calcium absorption is sub-optimal, serum 
calcium levels decrease which in turn stimulates the pro-
duction of PTH from the parathyroid glands [81]. This 
increases the reabsorption of calcium and enhances 
the expression of the receptor activator of nuclear fac-
tor kappa B (NFκB) ligand (RANKL) on osteoblasts to 
increase the production of mature osteoclasts which 
mobilizes calcium to bone, restoring serum calcium con-
centrations to normal [82]. PTH also mobilizes phospho-
rous from bone, as well as decreases kidney phosphorous 
reabsorption which causes phosphaturia [82]. Since PTH 
is regulated by calcium intake, it has been suggested that 
serum PTH measurements be taken if serum calcium is 
abnormal to determine the cause of abnormality [66].
Therefore, calcium and vitamin D deficiency are par-
ticularly important role players in bone health, because 
reduced calcium absorption increases PTH concentra-
tion and accelerates the rate of bone loss, which raises the 
number and activity of osteoclasts that release calcium 
from bone. Though this is an appropriate short-term 
homeostatic response, the long-term effects are detri-
mental to the skeleton because of the ongoing imbalance 
at the remodelling sites.
Additionally, locally produced growth factors such as 
insulin-like growth factor (IGF)-1 and -2, transforming 
growth factor (TGF)-β, interleukins (IL)s, prostaglan-
dins, tumour necrosis factor (TNF)-α and osteoprotegrin 
ligand (OPG-L) have also been implicated as regulators of 
bone remodelling, together with the hormones oestrogen 
and androgens. These factors will be discussed at a later 
stage in this review.
Clinical significance of BMD measurements
Bone status is largely absent in SA due to lack and cost 
of specific equipment for assessing BMD. A few studies 
suggested that BMD in Africa may be similar to northern 
world observations, however, the prevalence of fractures 
appears to be much lower [83–85].
With the use of alternative measuring techniques that 
are readily available for BMD, the cost will decrease; 
however, the precision of other bone density measuring 
techniques compared to DEXA is still not agreed upon. 
Nevertheless, the potential of diagnosing a person with 
the predisposition of developing osteoporosis, using easy 
to use equipment and markers associated with BMD is 
warranted as proper and earlier treatment may prevent 
or even delay the onset of osteoporosis. Confirmation 
however is still necessary with the use of a DEXA scan. 
HIV specifically has a negative impact on BMD and will 
be the focus of the next section.
HIV
HIV disease profile
With HIV infections, various complications arise which 
affect different systems of the body. These include car-
diac, metabolic, endocrine, renal and inflammatory/
immune systems to name but a few. Apart from these 
complications, changes in lipid and glucose metabolism, 
adipose tissue disorders and abnormal bone metabolism 
are also prevalent. One of the major focuses of research 
Fig. 3 The restoration of suboptimal calcium levels
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has been the association between HIV, HAART, meta-
bolic disorders and vascular disease. However, the spe-
cific effects of HIV on the metabolic, endocrine and 
renal systems, as well as the bone, and the interactions 
between these systems have not been that extensively 
studied. Furthermore, although the use of HAART has 
improved the prognosis of HIV-infected patients dramat-
ically, long-term HAART is associated with several car-
dio-metabolic, endocrine, renal and bone perturbations, 
which will be discussed in the next section.
HIV and the metabolic system
Insulin resistance, impaired glucose tolerance, impaired 
fasting glucose and diabetes mellitus (DM) are a spec-
trum of glucose metabolism disorders reported in per-
sons with HIV infection both with and without HAART. 
In a HIV-positive population, approximately 25–35% of 
patients have impaired glucose tolerance, whereas 2–7% 
have DM [86, 87]. Genetic susceptibility and lifestyle 
seem to be some of the factors that most often cause vari-
ation in the prevalence of HIV from one population to 
another [87].
There is a strong association between insulin resistance 
and lipid accumulation in muscle and liver tissue in HIV-
positive patients with lipodystrophy—increased VAT is 
associated with excess free fatty acids, increased intramy-
ocellular fat content and reduced adiponectin [88]. Glu-
cose uptake into abdominal subcutaneous adipose tissue 
(SAT) is increased in HIV-infected patients, whereas glu-
cose uptake in VAT and muscle cells does not differ [88].
With specific reference to BMD, inconsistencies exist 
regarding the relationship between VAT and BMD. 
Whilst some studies suggest an inverse relationship [89, 
90], a study by Yamaguchi et al. suggests a potential pro-
tective effect of VAT especially in patients with DM [91]. 
A study by Bredella et  al. confirmed the findings of an 
inverse relationship between VAT and BMD in pre-men-
opausal obese women [92]. They further go on to suggest 
that this effect may at least by partially mediated by IGF-
1, since IGF-1 and muscle mass are positive predictors of 
BMD. The growth hormone (GH)/IGF-1 axis is a major 
determinant of BMD [93, 94] and seems to be dysregu-
lated in females specifically in proportion to the degree 
of VAT [95]. Other potential explanations could include 
the release of proinflammatory cytokines secreted by 
adipocytes, such as IL-6, TNF-α, and adipokines, such as 
E-selectin and adiponectin, stimulating osteoclast activ-
ity [90, 96, 97].
A previous study also found that lean body mass is an 
important predictor of BMD in premenopausal women, 
whereas fat mass correlated positively with BMD of the 
hip [98]. The adipokine, leptin, is responsible for regulat-
ing several hypothalamic pituitary adrenal (HPA) axes 
which are involved in mediating the connection between 
leptin and bone by means of direct and indirect mech-
anisms. Since the leptin receptor can be found in adult 
primary osteoblasts, it is suggested that leptin has a 
direct effect on bone growth through its inhibitory action 
against bone resorption (osteoblastic activity) [99]. It reg-
ulates osteocalcin which in turn regulates bone metabo-
lism [100]. Furthermore, bone marrow adipocytes also 
secrete leptin which may mediate leptins’ local effect on 
bone. On the other hand, indirect mechanisms are more 
complex and involve cortisol, thyroid and parathyroid 
hormones, as well as growth hormones and IGF-1 [101].
HIV and the endocrine system
A wide spectrum of endocrine complications is associ-
ated with HIV infection and acquired immunodeficiency 
syndrome (AIDS). However, these disorders may also be 
as a consequence of systemic illness, opportunistic infec-
tions, body composition and/or HIV-related therapies 
[102]. The pituitary, thyroid, adrenal gland, gonadal, pan-
creas and bone are all involved.
Although HIV brings about secondary issues such as 
endocrine dysregulation, hormonal imbalances are not a 
common occurrence. HIV does however involve almost 
all of the hormonal systems and axes. One of the most 
common endocrine axes to be affected by HIV is the 
HPA axis [103]. During a condition such as HIV, viral 
proteins and cytokines activate or inhibit the hormonal 
system, further contributing to HPA dysregulation, a 
condition which is exacerbated with HAART [103]. The 
adrenal gland malfunctions as a result of adrenal insuf-
ficiency. Furthermore, due to a glucocorticoid resistant 
state, impaired adrenal and pituitary reserves cannot 
react to increased cortisol levels. Various different thy-
roid hormone disorders also occur which is associated 
with altered metabolism, poor oral intake and increased 
prevalence of weight loss and wasting syndrome [103].
Oestrogens and androgens have also been implicated 
to contribute to changes in BMD, not only during adult-
hood, but also during the growth of the skeleton. Oes-
trogen specifically has been shown to inhibit osteoclast 
function, and stimulate osteoblasts to produce growth 
factors and cytokines that mediate oestrogen’ action, 
some of which regulate the osteoblasts indirectly [104]. 
More importantly, oestrogen may play a role in determin-
ing the life span of bone cells by controlling the rate of 
apoptosis, thus decreasing the lifespan of osteoblasts and 
increasing the longevity of osteoclasts [104]. Two specific 
and complementing mechanisms have been implicated 
to explain the effect of oestrogen on bone. Firstly, oes-
trogen deficiency (most commonly as a result of meno-
pause) causes bone loss through its activation of new 
bone remodelling sites and through exaggeration of the 
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imbalance between bone formation and resorption [104]. 
Oestrogen deficiency stimulates osteoblast production 
of IL-1 and -6 and TNF-α and inhibits apoptosis, thus 
extending the life span of osteoclasts. Oestrogen defi-
ciency decreases IL-1ra leading to enhanced osteoclast 
sensitivity to IL-1. These actions mainly occur via oestro-
gen receptor (ER)α, which then elicits a prominent effect 
on the regulation of bone turnover and the maintenance 
of bone mass [105]. Although osteoblast numbers are 
also elevated, the increase in bone formation is not suffi-
cient to replace the bone matrix removed by osteoclasts, 
resulting in net bone loss.
One has to take into consideration that HIV-infected 
subjects already have low BMD, and even more so when 
treated with HAART. Given the vast proportion of 
women living with HIV, who are and will be transition-
ing through menopause, one also needs to consider the 
additional burden that low oestrogen levels will place on 
a BMD level that is already compromised by HIV and 
HAART. Statistics in the USA are largely alarming, as it 
is anticipated that by 2020, more than 50% of HIV infec-
tion will be in patients over the age of 50 years [106]. In 
women living with HIV, an intricate relationship between 
HIV and menopause appears to exist in that HIV may 
influence the natural history, experience, and complica-
tions of menopause, while menopause itself could poten-
tially influence the course of HIV infection [107]. This 
relationship between HIV and menopause further com-
plicates the management of HIV infection in women as 
they age and challenges clinicians, since lymphocyte sub-
sets, including CD4 counts have been found to decrease 
with increasing age in non-HIV-infected adults [108]. 
Considering that older individuals are usually diagnosed 
later with a more advanced stage of HIV, CD4 counts will 
be even lower. Therefore, the combination of all of these 
factors predisposes women to an earlier and even more 
severe bone loss compared to those individuals without 
HIV.
In males, testosterone affects BMD through its direct 
effect on the androgen receptors in trabecular and cor-
tical bone [109, 110]. Testosterone’s effect is more com-
plex than that of oestrogen as it is converted to estradiol 
in adipose tissue or bone, with subsequent stimulation of 
the oestrogen receptors [110–112]. When androgen lev-
els are low, it is associated with bone loss and increased 
bone remodelling in men [113, 114]; however, a reduction 
in oestrogen seems to play a key role in the age-related 
decrease of BMD [115, 116]. With advancing age, testos-
terone is also considered the major source of circulating 
estradiol in women (menopause), and testosterone can 
regulate local production of cytokines and growth fac-
tors in bone, including IL-6, IL-1β, TGFβ and IGFs [109]. 
The anabolic effects of testosterone on muscle mass and 
strength can also indirectly affect bone mass.
Data on the effect of low testosterone levels on BMD 
are not in agreement. One specific study suggests that 
serum total estradiol, but not testosterone is associated 
with reduced BMD in HIV-infected men [117]. This 
study showed that among men with low testosterone, it is 
only those men that develop an oestrogen deficiency that 
will have lower BMD, a result which was also evident in 
other studies [118, 119], although some studies found the 
opposite to be true [120, 121].
It is therefore evident that older age, and therefore the 
decrease in sex hormones, impacts BMD even more neg-
atively when associated with HIV and HAART treatment.
HIV and the renal system
Patients with HIV usually show signs of proteinu-
ria which progress rapidly to end-stage renal disease, 
commonly referred to as HIV-associated nephropathy 
(HIVAN) [122]. The nucleoside reverse transcriptase 
inhibitor (NRTI), tenofovir (TDF), has been linked to 
proximal renal dysfunction (PRTD), which can result in 
excessive renal phosphate, uric acid and bicarbonate loss. 
Furthermore, it can also result in proteinuria and gluco-
suria especially in patients with pre-existing nephropa-
thy [123]. A study by Fux et al. showed that PRTD may 
promote BMD loss through renal phosphate wasting 
[124]. Studies originally reported on nephrotoxic effects 
as a result of TDF, but the incidence of adverse renal 
effects were low in initial randomized trials [125, 126]. A 
small but significant loss in renal function was observed 
in patients on TDF-containing regimens compared to 
abacavir (ABC)-containing regimens [127]; however, 
studies are not conclusive regarding renal endpoints 
and more patients developed clinical renal impairment 
[128, 129]. Additionally, although both the STEAL and 
ASSERT study indicated no difference in estimated glo-
merular filtration rate (eGFR) between patients [130, 
131], increases in markers of proximal tubule dysfunction 
were evident as a result of TDF treatment in the ASSERT 
study [130]. This is comparable to results obtained by 
Rasmussen et al. In this particular study, although no dif-
ference in renal function was evident when plasma cysta-
tin C (cysC) and estimated creatine clearance (CrCl) were 
measured (indicative of stable GFR), a minor increase 
in urinary neutrophil gelatinase-associated lipocalin 
(NGAL)/creatinine ratio (as a marker of renal dysfunc-
tion) was observed in the TDF-containing regimen com-
pared to the ABC-containing regimen [132]. CrCl is 
however dependent on factors other than plasma creati-
nine and GFR, such as changes in muscle mass and tubu-
lar secretion of creatinine.
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A different formulation of TDF was approved by the 
FDA in order to try and overcome the side effects asso-
ciated with TDF. Patients that switched to tenofovir 
alafenamide (TAF) seemed to be more likely to keep their 
viral load low, whilst kidney function and bone density 
was improved [133, 134]. Even after 2–3 years, TAF was 
better at suppressing viral load and safer for the bones 
and kidneys [135, 136]. A similar study by Brown et al., 
also showed that participants who switched from TDF to 
TAF showed improved bone health, including a reduc-
tion in osteoporosis [137].
HIV and bone mineral density
A reduction in BMD is a common complication of HIV 
and its treatment, with low BMD, osteopenia and osteo-
porosis more commonly associated with both male and 
female HIV-infected subjects [138, 139], compared to 
non-infected subjects [140, 141].
The rates of osteopenia and osteoporosis were found to 
be as high as 67 and 15% respectively, whilst the magni-
tude of BMD reduction was 6.4-fold higher, and that of 
osteoporosis 3.7-fold higher in HIV-positive patients, 
as reported in a meta-analysis [142]. Cazavane et  al. 
indicated that more than half the HIV-infected patients 
had osteopenia, and approximately a third had osteopo-
rosis [138], results which were verified by a study from 
McComsey et al. [143]. Triant et al. also reported a higher 
prevalence of fracture risk in HIV-positive patients com-
pared to HIV-negative patients [144]. A more recent 
study reported the rates for osteopenia and osteoporosis 
to be 47.5 and 23% respectively, whilst BMD decreased 
in about 28% of subjects in a follow-up study of 2.5 years 
[145]. Sharma et al. found similar results, where rates of 
42 and 12% were reported for osteopenia and osteopo-
rosis respectively—the degree of osteopenia was three 
times higher in the HIV-infected subjects with 12% of 
patients progressing to osteoporosis [146]. These studies 
highlighted the existence of high prevalence of osteope-
nia and osteoporosis in the HIV-positive population.
HIV-positive patients have reduced bone size, mass 
and strength due to altered metabolism and the infec-
tion of bone cells [147]. It has been suggested by Duvivier 
et al. and Borderi et al. that HIV infection of osteoblasts 
may be related to a negative balance of bone remodelling 
[148, 149]. Since osteopenia and osteoporosis is highly 
prevalent in HAART-naïve patients, it suggests that if 
viremia is not controlled properly, it might impact BMD 
via its effects on persistent systemic inflammation and 
bone remodelling. Not only do the HIV proteins increase 
osteoclast activity, but they promote osteoblast apopto-
sis, thereby decreasing bone formation [150].
Under normal conditions, both vitamin D and phos-
phate metabolism are important for skeletal integrity; 
however, in HIV, vitamin D and phosphate contributes to 
low BMD due to impaired mineralization [148]. Approxi-
mately 60–75% of patients in a HIV-infected population 
have low vitamin D levels [151]. Furthermore, hypo-
gonadism may also play a role [152], and lipoatrophy 
seems to mediate bone loss through adipocyte hormone 
signalling [89].
Since persistent systemic inflammation can impact 
bone density, the involvement of various cytokines 
involved in this process are of great importance. T-cells 
(specifically targeted by HIV infection), B-cells and 
monocytes are responsible for the production and regu-
lation of key osteoclastogenic cytokines such as RANKL 
and OPG [153]. It is speculated that HIV infection results 
in the alteration of B cell function and subsequently a 
switch from bone sparing OPG production to the pro-
duction of bone destroying RANKL, thus leading to 
increased osteclastogenesis [154]. This data is consistent 
with the fact that B-cells are mainly regulated by interac-
tions with T-cells, as well as the fact that severe perturba-
tions of the B-cell linage are mediated by HIV infection 
(through direct effects of viral infection and/or indirectly 
though disruption of co-stimulatory signals from T-cells 
and other disrupted immune components) [155, 156]. 
Along with upregulation of RANKL by HIV gp120 pro-
tein, there is further activation of RANKL by TNF-α that 
is represented in higher numbers in advanced HIV dis-
ease [157].
A dramatic increase in the number of osteoclast pre-
cursors (defined as monocytes expressing the RANKL 
receptor, RANK) were also evident, whilst OPG expres-
sion was significantly diminished [156]. Data from animal 
studies showed that HIV infection results in alterations 
in the immuno-skeletal interface favourable to acceler-
ated bone resorption and loss of bone mass. Low serum 
OPG concentrations have been reported in HIV/AIDS 
patients [158], verifying some of the data seen from ani-
mal studies. Furthermore, peripheral blood T-cells have 
been implicated as a potential source of OPG [158]. 
Other studies have shown that HIV-infected women have 
higher levels of both RANKL and OPG than their HIV-
negative counterparts, suggesting increased overall bone 
turnover in HIV-infected patients [159], while HAART 
initiation has been associated with increases in both, 
again suggesting increased bone turnover [160, 161].
One of the most recent studies performed were able to 
show that the combination of all B cells were responsible 
for the increase in RANKL, whilst the decrease in OPG 
was due to changes in the distribution of B cell subsets 
[162]. Therefore it is crucial to distinguish between the 
different B cells and to include naïve and resting mem-
ory B cells (decreased number with high expression of 
OPG), and tissue-like B cells (increased number with 
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low expression of OPG). When the relationship between 
these markers and BMD in HIV-positive participants was 
investigated, RANKL/OPG correlated significantly with 
BMD and T- and/or Z-scores in the femur neck and hip 
region, which was not evident in the HIV-negative partic-
ipants. The data therefore supports the concept of B cell 
alterations in RANKL and OPG production which may 
contribute to the decline in BMD in the context of HIV. 
Interestingly, although a decrease in OPG expression in 
the B cells was observed overall, serum OPG levels were 
elevated whilst RANKL was decreased, which was also 
shown in other studies [163, 164]. However, whereas 
some of the studies showed a decrease in RANKL, the 
study by Gibellini et al. indicated an increase in RANKL 
suggesting that relying only on circulating markers is not 
a true reflection of what happens in bone.
Interferon (IFN-γ) has also been shown to inter-
fere with the RANKL receptor through its action on 
the adapter protein, (tumour necrosis factor receptor-
associated factor-6; TRAF-6) that links RANK to its 
downstream transcription factors, ultimately inhibit-
ing osteoclast formation [165, 166]. These alterations in 
the immune-skeletal interface may therefore account for 
much of the loss of BMD observed in HIV patients.
Even though there are growing concerns regard-
ing osteoporosis, the impact of HIV and its treat-
ment on bones in resource-limited countries is poorly 
documented.
HAART and bone mineral density
Various studies have reported on low BMD in HIV-
infected adults; however, the prevalence of osteoporosis 
seems to be approximately three times higher in HIV-
infected patients receiving HAART treatment than unin-
fected patients [142]. Although studies reported a 2–6% 
decrease in BMD (within the first 2 years) with HAART 
treatment [149, 167], this decline in BMD only pertains 
to patients starting a new HAART regimen (within 
24–48  weeks) [149, 168], and not continuing on a cur-
rently established regimen. This decrease seems to be 
similar to that observed within the first 2 years of meno-
pause [169].
From the literature it is evident that the specific type 
of treatment can have a significant effect on bone loss. 
The use of NRTIs has been associated with low BMD 
[160, 168, 170]. TDF-based treatment patients had a 
much lower BMD after 96 weeks of treatment compared 
to other regimens such as lamivudine (3TC) and emtric-
itabine (FTC) patients, although no higher incidence of 
fracture were evident [160, 168, 170]. Similar results were 
obtained in a study using ABC as alternative [160].
Results from the study of Cotter et al. showed no sig-
nificant alteration in phosphate metabolism that often 
accompanies bone loss [171], although some studies have 
shown TDF is able to decrease BMD through persistent 
urinary loss of phosphates [170, 172]. Instead, higher 
serum phosphorus among patients with low bone density 
was evident, although it is not exactly clear why. Further-
more, time on TDF showed a trend to correlate with low 
BMD Z-scores, which is in direct contrast to other stud-
ies which have failed to show any correlation between 
TDF and low bone mass, even after long-term exposure 
to the drug [173, 174]. NRTIs can further reduce BMD by 
elevating lactic acidemia, a mechanism related to calcium 
hydroxyapatite loss, especially in the trabecular bone, 
due to the lability of calcium storage [175]. Several stud-
ies have directly highlighted HIV factors associated with 
low BMD: duration of infection, HIV viral burden, and a 
more advanced HIV disease [171].
Studies regarding PIs remain unclear due to conflicting 
results. PI use has been shown to result in increased bone 
turnover, accelerated bone loss, and a higher prevalence 
of reduced BMD [142, 149, 170, 176], whilst other studies 
failed to show such a difference [167, 177–179]. A recent 
study conducted in Asia by Kinai et al. indicated that PI 
use, but not specific type of PI, was the most significant 
cause of low BMD at both spine and femoral neck [180]. 
This finding is consistent with an in vitro study evaluat-
ing the effect of different PIs on osteoblast activity [181]. 
Kinai et  al. also observed a large difference in BMD 
between PI-discontinued and continued patients—PI dis-
continued patients displayed BMD levels in the lumber 
spine and not femoral neck [180], consistent with other 
studies [149, 170]. This is likely due to the fact that the 
femur contains cortical substance with few osteoclasts, 
whilst the vertebrae contain osteoclast-rich trabecu-
lar substance. Interestingly, discontinuation of ritonavir 
(RTV), an osteoclast-activating agent, resulted in slower 
decrease in BMD in vertebrae compared to the femoral 
neck [180]. Furthermore, RTV was able to cause bone 
mineral loss in a time dependent manner irrespective of 
dosage [180]. RTV was also shown to promote the prolif-
eration and activation of osteoclasts in both in vitro [182, 
183] and ex  vivo studies [184], causing increased bone 
absorption.
In a study by Duvivier et al., a four percent decline in 
BMD were evident after 48 weeks on HAART in the lum-
bar spine and a three percent decline in hip BMD [149]. 
Although BMD loss occurred with PIs, NNRTIs alone, 
as well as a combination of PIs and NNRTIs, could not 
worsen the BMD loss in the spine [149]. In contrast, a 
significant loss in BMD (5–6%) at the femoral neck by 
week 48 were evident irrespective of NRTI or PIs [185].
Specific BMD measurements with DEXA showed that 
immune suppression before starting HIV therapy was a 
risk factor for loss of BMD during treatment. However, 
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there was no evidence that the extent of immune recon-
stitution was associated with BMD change after con-
trolling for baseline  CD4+ count even with HAART 
initiation—loss of bone continues after HIV therapy is 
initiated (up to 2  years) [186]. Data therefore suggests 
that low pre-treatment CD4 count, but not early change 
with HAART was a strong and independent risk factor 
for bone loss after HAART initiation—providing further 
evidence for the benefits of early initiation of HAART 
[186].
Although HAART may be associated with the occur-
rence of fractures, none of the studies thus far were able 
to show any changes in fracture rates. This is possibly due 
to the limited number of cohort studies exploring this 
phenomenon, as well as a too short follow-up period.
The mechanisms of action of HAART‑induced bone loss
The specific mechanisms by which HAART induces 
bone loss remain debatable, but it has been thought to be 
either due to a direct effect on bone cells (most likely), 
realignment of HIV-associated pathologies resulting 
from disease reversal, or a combination of these factors. 
In vitro and in vivo studies involving animal models have 
shown that HAART do act on osteoclasts and osteo-
blasts; however, these effects could not be verified in 
humans due to the different effects the different HAART 
classes have on bone. One such example was found in a 
study by Wang et  al. in which the PI, RTV, suppressed 
osteoclastogenesis and osteoclast function in  vitro and 
in vivo by impairing RANKL-induced signalling, but the 
PI indinavir (IDV) had no effect on osteoclastogenesis 
[187]. The PI fosamprenavir (FPV) significantly increased 
OPG and decreased RANKL production  in vitro, which 
could suggest protection of bone mass if confirmed 
in vivo. In contrast, other PIs including atazanavir (ATV), 
saquinavir (SQV), and IDV failed to impact the OPG/
RANKL ratio [181]. Furthermore, preliminary studies in 
vitro have found no effect of several NRTIs on osteoclas-
togenesis, but NRTIs were found to suppress osteoblast 
activity instead [188].
Confounding factors and discrepancies in results
Many confounding factors are assumed to play a role in 
the pathogenesis of decreased bone mass in HIV-infected 
patients [189]. Fat-free mass, one of the most important 
components of body composition was shown to be one 
of the problems [190]; however, according to Reid et  al. 
[191], low weight appears to be the major component 
in healthy individuals, which has also been verified in 
a HIV-positive population [147]. Results from a more 
recent study are in accordance with the important role of 
body composition and have indicated that weight, BMI, 
and body fat were all associated with BMD, especially in 
females [192], which also highlights the importance of 
nutrition on BMD, especially because low calcium and 
vitamin D intake reduces BMD [193]. A study in Brazil 
indicated that HIV-positive populations have calcium 
and vitamin D deficiencies, even though their dietary 
intake is similar to that described in other young Brazil-
ian populations [194, 195]. Limitations in studies regard-
ing nutrition and BMD are often due to the fact that 
participants need to recall what they have consumed and 
errors might slip in as it is self-reported. Low BMD have 
been linked to low body weight, testosterone or oestro-
gen deficiency, glucocorticoids, malabsorption, tobacco 
use, alcohol and opiate abuse, nadir CD4 cell count, dura-
tion of HIV infection, lipodystrophy, insulin resistance 
and hyperlactatemia, all of which could contribute to the 
discrepancies in results [196].
Conclusions
Although bone loss is a common complication of HIV, 
HAART initiation further worsens, rather than ame-
liorates, bone loss. This effect of HAART on BMD is 
rather alarming in a population whose skeletal integrity is 
already seriously compromised due to HIV infection. The 
interaction between bone and the endocrine, metabolic 
and renal system in this population complicates bone 
dynamics even further. Opinions still differ widely among 
investigators as to the direct effects of HAART or their 
components on bone cells, or their mechanisms of action 
on the skeleton. Consequently, it is rather thought that 
all HAART formulations may be inherently detrimental 
to the skeleton as bone loss appears to be a general phe-
nomenon observed following HAART initiation, regard-
less of the regimen type, although PIs and specifically 
TDF may be the main causes.
Various studies found that continuous exposure to 
HAART results in a further decline in BMD compared 
with intermittent HAART exposure. Although most of 
the important questions regarding HAART-related bone 
loss are now answered, such as: (1) Are certain HAART 
regimens more detrimental than others? (2) How soon 
after HAART initiation does bone loss begin? and (3) 
Does it occur in a specific timeframe or is it a long-term 
effect? the fact still remains that HAART treatment has a 
negative influence on BMD.
The NRTI, TDF has been associated with bone loss 
in various studies compared to other regimens. PIs on 
the other hand have also been associated with skeletal 
deterioration in most studies. While the degree of bone 
loss may vary somewhat between regimens, almost all 
HAART regimens resulted in a significant loss of BMD 
between 2 and 6% over time. The biggest loss following 
HAART initiation appears to occur within 24–48 weeks. 
Furthermore, once lost, BMD never recovers to 
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pre-treatment baseline levels, let alone to normal BMD 
levels characteristic of uninfected individuals of similar 
age. Therefore, it is imperative that BMD be monitored 
and treatment started if a patient is diagnosed with low 
BMD.
Determining BMD in a specific population also appears 
to be somewhat of a concern, since the gold standard 
method to determine BMD, the DEXA, is not readily 
available in all clinics and areas. The ability to use other 
assessment tools such as QUS in resource limited settings 
will have to be investigated, but validation of the method 
needs to first take place before being able to use it as a 
diagnostic and research tool for a specific population.
Take home message to clinicians The primary goal for 
any clinician in treating people with osteoporosis is pre-
venting fractures. However, when the patient is faced 
with HIV or even the additional burden of HAART treat-
ment, the strategies should probably have to be altered. 
With respect to BMD management, those individuals 
with HIV should undergo the same treatment process 
as HIV-negative people, and should also include lifestyle 
modifications and pharmacological interventions. This 
will be of great benefit not only when BMD is low, but 
will also benefit those individuals with HIV. One should 
always bear in mind that certain pharmacological inter-
ventions for other conditions, may have interactions 
with HAART medication in HIV subjects and might not 
be safe to use. Some of the medications taken for oste-
oporosis have also not been tested in combination with 
the various HAART treatment options. These patients 
should therefore be carefully monitored for a couple of 
months to establish whether any side effects arose as a 
consequence of treatment. For the most part, the benefits 
of HAART with respect to virologic control are consid-
ered to outweigh the risk of potentially exacerbating bone 
loss. However, in those patients who are at high risk of 
a fracture, clinicians may want to consider avoiding TDF 
or PIs if alternatives are available. When also faced with 
the additional burden of menopause, one has to take into 
consideration that oestrogen is also now low, and that if 
oestrogen is given additionally, it might have an effect 
or even interfere with the other medications already 
prescribed.
Usage of FRAX is recommended, and secondary causes 
of osteoporosis other than HIV or menopause should be 
evaluated. Patients at high risk for fractures should be 
encouraged to make lifestyle changes, to avoid tobacco 
and alcohol, and to prevent falls. Once osteoporosis has 
been diagnosed and therapy started, DEXA should be 
repeated every 1–2 years as follow-up.
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